JP6877357B2 - Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 - Google Patents

Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 Download PDF

Info

Publication number
JP6877357B2
JP6877357B2 JP2017553974A JP2017553974A JP6877357B2 JP 6877357 B2 JP6877357 B2 JP 6877357B2 JP 2017553974 A JP2017553974 A JP 2017553974A JP 2017553974 A JP2017553974 A JP 2017553974A JP 6877357 B2 JP6877357 B2 JP 6877357B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017553974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512435A5 (cg-RX-API-DMAC7.html
JP2018512435A (ja
Inventor
ロバート・シー・ポーディ
シャオビン・チエン
スティーヴン・ドナヒュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2018512435A publication Critical patent/JP2018512435A/ja
Publication of JP2018512435A5 publication Critical patent/JP2018512435A5/ja
Application granted granted Critical
Publication of JP6877357B2 publication Critical patent/JP6877357B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017553974A 2015-04-15 2016-04-15 Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 Active JP6877357B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562147853P 2015-04-15 2015-04-15
US62/147,853 2015-04-15
US201562234899P 2015-09-30 2015-09-30
US62/234,899 2015-09-30
US201562261528P 2015-12-01 2015-12-01
US62/261,528 2015-12-01
PCT/US2016/027774 WO2016168613A1 (en) 2015-04-15 2016-04-15 Methods of increasing strength and functionality with gdf8 inhibitors

Publications (3)

Publication Number Publication Date
JP2018512435A JP2018512435A (ja) 2018-05-17
JP2018512435A5 JP2018512435A5 (cg-RX-API-DMAC7.html) 2019-05-09
JP6877357B2 true JP6877357B2 (ja) 2021-05-26

Family

ID=55809250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553974A Active JP6877357B2 (ja) 2015-04-15 2016-04-15 Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法

Country Status (14)

Country Link
US (3) US10934349B2 (cg-RX-API-DMAC7.html)
EP (1) EP3283519A1 (cg-RX-API-DMAC7.html)
JP (1) JP6877357B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240128136A (cg-RX-API-DMAC7.html)
CN (1) CN107771081A (cg-RX-API-DMAC7.html)
AU (1) AU2016249015B2 (cg-RX-API-DMAC7.html)
CA (1) CA2982810A1 (cg-RX-API-DMAC7.html)
EA (1) EA201792298A1 (cg-RX-API-DMAC7.html)
HK (1) HK1250236A1 (cg-RX-API-DMAC7.html)
IL (1) IL255010B2 (cg-RX-API-DMAC7.html)
MA (1) MA49661A (cg-RX-API-DMAC7.html)
MX (1) MX2017013267A (cg-RX-API-DMAC7.html)
WO (1) WO2016168613A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201707550B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
KR102269708B1 (ko) 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
IL278014B2 (en) 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
MX2017013267A (es) 2015-04-15 2018-08-15 Regeneron Pharma Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8).
ES3030258T3 (en) 2015-09-15 2025-06-27 Scholar Rock Inc Anti-pro/latent-myostatin antibodies and uses thereof
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
KR102271635B1 (ko) * 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
HUE061656T2 (hu) 2017-01-06 2023-07-28 Scholar Rock Inc Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával
JP7579706B2 (ja) * 2018-03-01 2024-11-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 体組成を変更するための方法
EP4596043A3 (en) 2018-04-06 2025-10-01 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
KR20210104744A (ko) * 2018-12-18 2021-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법
CN111303280B (zh) * 2020-03-22 2022-01-07 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用
CN117083065A (zh) 2020-10-30 2023-11-17 庆应义塾 肌肉减少症相关疾病等的新颖治疗和预防
EP4470563A1 (en) 2022-01-25 2024-12-04 Motoshi Hayano New therapy and prevention for suppressing aging-related disorders including sarcopenia
AU2023413166A1 (en) 2022-12-22 2025-07-03 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1910220A (en) * 1931-10-21 1933-05-23 Kremser Alois Mechanically operated gate
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
EP1333035A3 (en) 1993-03-19 2004-07-07 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6368597B1 (en) 1998-05-06 2002-04-09 Matamorphix, Inc. Methods of treating diabetes
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
CN1384757A (zh) 1999-07-20 2002-12-11 法麦克萨有限公司 下调gdf－8活性的方法
US6670140B2 (en) 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
MXPA05012965A (es) 2003-06-02 2006-03-09 Wyeth Corp Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello.
WO2005066204A2 (en) 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
AU2005219441A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. ALK7 and myostatin inhibitors and uses thereof
ATE557042T1 (de) 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
AU2005272646A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
AU2006239860B2 (en) 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
JP5065253B2 (ja) 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１モノクローナル抗体とその使用法
EP1773041A1 (en) 2005-07-21 2007-04-11 Chao-Hung Wu Audio/video data transmission system using the internet to interconnect telephones
MX2008002367A (es) 2005-08-19 2008-03-18 Wyeth Corp Anticuerpos antagonistas contra el factor 8 de crecimiento y diferenciacion y usos en el tratamiento de esclerosis lateral amiotrofica y otros trastornos relacionados con el factor 8 de crecimiento y diferenciacion.
US7635760B2 (en) 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US20070149458A1 (en) 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
EP2054434B1 (en) 2006-08-03 2017-03-15 Myostin Therapeutics Pty Ltd Myostatin antagonists
UA98308C2 (en) 2006-09-05 2012-05-10 Эли Лилли Энд Компани Anti-myostatin antibody
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
AR069165A1 (es) 2007-11-05 2010-01-06 Novartis Ag Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
WO2010019261A1 (en) 2008-08-14 2010-02-18 Acceleron Pharma Inc. Use of gdf traps to increase red blood cell levels
TW201029662A (en) * 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
DK2424895T3 (en) 2009-04-27 2017-12-18 Novartis Ag Compositions and Methods for Increasing Muscle Growth
KR20120027055A (ko) 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
EA201390242A1 (ru) 2010-08-16 2013-07-30 Амген Инк. Антитела, связывающие миостатин, композиции и способы
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
EP3824890A1 (en) 2011-05-16 2021-05-26 Genzyme Corporation Induction of immune tolerance using methotrexate
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
NZ702269A (en) 2012-06-15 2017-07-28 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
WO2014022540A1 (en) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
EA201591423A1 (ru) 2013-02-01 2016-01-29 Санта Мария Биотерапевтикс, Инк. Введение антитела к активину-а пациентам
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
CN105960414A (zh) * 2013-08-14 2016-09-21 诺华股份有限公司 治疗散发性包涵体肌炎的方法
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
MX2017013267A (es) 2015-04-15 2018-08-15 Regeneron Pharma Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8).
WO2018009732A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
JP7579706B2 (ja) 2018-03-01 2024-11-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 体組成を変更するための方法

Also Published As

Publication number Publication date
ZA201707550B (en) 2018-11-28
KR20170135967A (ko) 2017-12-08
MX2017013267A (es) 2018-08-15
CN107771081A (zh) 2018-03-06
IL255010B1 (en) 2023-09-01
CA2982810A1 (en) 2016-10-20
KR20240128136A (ko) 2024-08-23
US12029788B2 (en) 2024-07-09
AU2016249015A1 (en) 2017-11-09
WO2016168613A1 (en) 2016-10-20
JP2018512435A (ja) 2018-05-17
IL255010A0 (en) 2017-12-31
IL255010B2 (en) 2024-01-01
EA201792298A1 (ru) 2018-04-30
MA49661A (fr) 2020-06-03
US10934349B2 (en) 2021-03-02
AU2016249015B2 (en) 2022-03-24
US20160304595A1 (en) 2016-10-20
HK1250236A1 (zh) 2018-12-07
US20210246198A1 (en) 2021-08-12
EP3283519A1 (en) 2018-02-21
US20240390489A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
JP6877357B2 (ja) Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
JP2022160619A (ja) 抗アクチビンａ抗体及びその使用
JP5896993B2 (ja) ヒトｇｄｆ８に対する抗体
AU2024202552A1 (en) Neutralization of inhibitory pathways in lymphocytes
KR20140123474A (ko) 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
BR112012001984B1 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
TW201902514A (zh) Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途
TWI747885B (zh) 用於治療類風濕性關節炎之組成物及方法
KR20230170796A (ko) 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
JP2021515003A (ja) 体組成を変更するための方法
JP2025134086A (ja) 関節リウマチを有する対象における疼痛を治療するための組成物および方法
KR20210122810A (ko) 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
IL280550B1 (en) A pharmaceutical preparation for the safe and effective treatment of knee and/or hip pain
KR20200083996A (ko) 인터류킨-17(il-17)을 사용하여 건병증을 치료하는 방법
KR20250011948A (ko) 인터류킨-17(il-17) 길항제를 사용하여 건병증을 선택적으로 치료하는 방법
US20240002491A1 (en) Methods for selecting patients for treatment with an ngf antagonist
EA040534B1 (ru) Способы увеличения безжировой массы тела с помощью антитела к gdf8 или его антигенсвязывающего фрагмента и тренировок с сопротивлением
KR20200039028A (ko) 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20180221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210427

R150 Certificate of patent or registration of utility model

Ref document number: 6877357

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE

Ref document number: 6877357

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250